Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)

Patent metadata

Field	Value
Publication number	US-10227351-B2
Application number	US-201815993669-A
Country	US
Kind code	B2
Filing date	May 31, 2018
Priority date	Nov 12, 2012
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

The invention relates to salt forms of (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methyl-thiomethyl)pyrrolidin-3-ol, as well as polymorphic forms of the salts. The invention further relates to processes for preparing the salt forms and to the use of the salt forms in the treatment of diseases and disorders where it is desirable to inhibit 5′-methylthioadenosine phosphorylase (MTAP).

First claim

The invention claimed is:

1. A process for preparing a compound of formula (V)

including the steps:
(d) reacting a compound of formula (III) with methyl chloroformate to produce a compound of formula (IV)

and
(e) cyclisation of the compound of formula (IV) under basic conditions to give the compound of formula (V);
wherein ethyl acetate is employed as a solvent in step (d).

Assignees

• Victoria Link Ltd

Inventors

• Evans Gary Brian
• Kelly Peter Michael
• Tyler Peter Charles

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D207/34

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title

• C07C53/06

  Salts thereof · CPC title